Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LATS1 | O95835 | 13/20 | 0.36 |
| ▸ | LATS2 | Q9NRM7 | 6/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21593630 | 0.87 | KMT2A (0.33) | LATS1LATS2KMT2A | |
| SCHEMBL2265828 | 0.74 | XDH (0.41) | KMT2ACSNK1A1CLK4ALDH1A1L3MBTL1 | |
| SCHEMBL21090137 | 0.74 | LATS1 (0.33) | LATS1LATS2CHRM4 | |
| SCHEMBL20980139 | 0.74 | KMT2A (0.35) | KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL31465483 | 0.74 | GSK3A (0.32) | — | |
| SCHEMBL17168791 | 0.74 | PIN1 (0.53) | KMT2AL3MBTL1 | |
| SCHEMBL1496403 | 0.74 | TDP1 (0.39) | KMT2ACSNK1A1CLK4ALDH1A1L3MBTL1 | |
| SCHEMBL23029862 | 0.72 | CSNK1A1 (0.38) | KMT2ACSNK1A1CLK4ALDH1A1L3MBTL1 | |
| SCHEMBL24620114 | 0.71 | PDE4A (0.39) | CSNK1A1CLK4 | |
| SCHEMBL24620414 | 0.71 | PDE4A (0.39) | CSNK1A1CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3418280-B1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INT (DE) | 2023-07-12 | — | — | EP | disclosed |
| EP-3131902-B1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INT (DE) | 2019-06-12 | — | — | EP | disclosed |
| US-20190002465-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INT (DE) | 2019-01-03 | — | — | US | disclosed |
| US-20180022749-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INT (DE) | 2018-01-25 | — | — | US | disclosed |
| US-20180022749-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INT (DE) | 2018-01-25 | — | — | US | disclosed |
| US-9598415-B2 | Compounds as modulators of RORγ | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-03-21 | — | — | US | disclosed |
| US-9598415-B2 | Compounds as modulators of RORγ | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-03-21 | — | — | US | disclosed |
| US-20170008894-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INT (DE) | 2017-01-12 | — | — | US | disclosed |
| US-20170008894-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INT (DE) | 2017-01-12 | — | — | US | disclosed |
| US-20160075706-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INT (DE) | 2016-03-17 | — | — | US | disclosed |
| US-9242989-B2 | Compounds as modulators of RORγ | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-26 | — | — | US | disclosed |
| US-9242989-B2 | Compounds as modulators of RORγ | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-26 | — | — | US | disclosed |
| WO-2015160654-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-22 | — | — | WO | disclosed |
| US-20150291607-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-15 | — | — | US | disclosed |
| US-20150291607-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022749-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | RORB, RORC, RORA | LATS1 4105/4885LATS2 4085/4885CHRM4 1365/4885 |
| US-20170008894-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | RORB, RORC, RORA | LATS1 4105/4885LATS2 4085/4885CHRM4 1365/4885 |
| US-20150291607-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | RORB, RORC, RORA | LATS1 4105/4885LATS2 4085/4885CHRM4 1365/4885 |
| US-20190002465-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | RORB, RORC, RORA | LATS1 4105/4885LATS2 4085/4885CHRM4 1365/4885 |
| US-20160075706-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | RORB, RORC, RORA | LATS1 4105/4885LATS2 4085/4885CHRM4 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.